Search research articles
Contact Us
Filters
Showing results (181-190 of 271) with videos related to
Page
of 28
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
November 20, 2008
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
Camilo Jimenez, Maria E Cabanillas, Libero Santarpia, et al.
Plos One
|
August 8, 2012
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling
Lorenzo Cohen, Steven W Cole, Anil K Sood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Tobias Else, Eric Jonasch, Othon Iliopoulos, et al.
Molecular Cancer Research : MCR
|
August 5, 2021
Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling
Michael H McGuire, Santosh K Dasari, Hui Yao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2012
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients
Arjan W Griffioen, Laurie A Mans, Annemarie M A de Graaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
Urologic Oncology
|
May 26, 2015
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation
Mehrad Adibi, Arun Z Thomas, Leonardo D Borregales, et al.
The Lancet. Oncology
|
September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
Othon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma
Jinhee Kim, Eric Jonasch, Angela Alexander, et al.
The New England Journal of Medicine
|
November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
Eric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 271) with videos related to
Sort By:
Page
of 28
The Journal of Clinical Endocrinology and Metabolism
|
November 20, 2008
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
Camilo Jimenez, Maria E Cabanillas, Libero Santarpia, et al.
Plos One
|
August 8, 2012
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling
Lorenzo Cohen, Steven W Cole, Anil K Sood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Tobias Else, Eric Jonasch, Othon Iliopoulos, et al.
Molecular Cancer Research : MCR
|
August 5, 2021
Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling
Michael H McGuire, Santosh K Dasari, Hui Yao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2012
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients
Arjan W Griffioen, Laurie A Mans, Annemarie M A de Graaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
Urologic Oncology
|
May 26, 2015
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation
Mehrad Adibi, Arun Z Thomas, Leonardo D Borregales, et al.
The Lancet. Oncology
|
September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
Othon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma
Jinhee Kim, Eric Jonasch, Angela Alexander, et al.
The New England Journal of Medicine
|
November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
Eric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
Page
of 28